H2 2020 Pipeline Review on Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – ResearchAndMarkets.com

H2 2020 Pipeline Review on Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – ResearchAndMarkets.com

H2 2020 Pipeline Review on Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report provides an overview of the Radiation Toxicity (Toxicology) pipeline landscape.

Radiation Toxicity (also known as radiation sickness) is an acute illness caused by irradiation of the entire body by a high dose of penetrating radiation in a very short period of time (usually a matter of minutes). The major cause of this syndrome is depletion of immature parenchymal stem cells in specific tissues. Symptoms include bleeding from the nose, mouth, gums, and rectum, bloody stool, bruising, confusion, dehydration, diarrhea, fainting and fatigue.

Report Highlights

The report provides comprehensive information on the therapeutics under development for Radiation Toxicity (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Radiation Toxicity (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 9, 7, 1, 49, 6 and 1 respectively. Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 6, 1 and 1 molecules, respectively.

Radiation Toxicity (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Radiation Toxicity (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Radiation Toxicity (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

  • Introduction
  • Radiation Toxicity – Overview
  • Radiation Toxicity – Therapeutics Development
  • Radiation Toxicity – Therapeutics Assessment
  • Radiation Toxicity – Companies Involved in Therapeutics Development
  • Radiation Toxicity – Drug Profiles
  • Radiation Toxicity – Dormant Projects
  • Radiation Toxicity – Discontinued Products
  • Radiation Toxicity – Product Development Milestones
  • Appendix

Companies Mentioned

  • 21st Century Therapeutics Inc
  • 9 Meters Biopharma Inc
  • Advanced Innovative Partners Inc
  • Advenchen Laboratories LLC
  • Amryt Pharma Plc
  • Angion Biomedica Corp
  • Aqualung Therapeutics Corp
  • Atox Bio Ltd
  • BCN Biosciences LLC
  • BioCurity Pharmaceuticals Inc
  • BioIncept LLC
  • Bolder Biotechnology Inc
  • Cellphire Inc
  • Ceramedix Holding LLC
  • Ceramide Therapeutics LLC
  • Chrysalis BioTherapeutics Inc
  • Cleveland BioLabs Inc
  • Consegna Pharma Inc
  • Creative Medical Technology Holdings Inc
  • Daiichi Sankyo Co Ltd
  • Eagle Pharmaceuticals Inc
  • Enzychem Lifesciences Corp
  • EpicentRx Inc
  • Exponential Biotherapies Inc
  • Extend Biosciences Inc
  • Fibreu Ltd
  • FirstString Research Inc
  • Foresee Pharmaceuticals Co Ltd
  • Genexine Inc
  • GNI Group Ltd
  • Humanetics Corp
  • Inflammatory Response Research Inc
  • iNtRON Biotechnology Inc
  • Jay Pharma Inc
  • KannaLife Sciences Inc
  • Luxena Pharmaceuticals Inc
  • Matrix Biomed Inc
  • Meabco AS
  • Medesis Pharma SA
  • Neumedicines Inc
  • New Amsterdam Sciences Inc
  • Nohla Therapeutics Inc
  • Novartis AG
  • Noveome Biotherapeutics Inc
  • Onconova Therapeutics Inc
  • Original BioMedicals Co Ltd
  • P2D Inc
  • PharmaIN Corp
  • Phoenicia Biosciences Inc
  • Pluristem Therapeutics Inc
  • Regeneus Ltd
  • RepoCeuticals ApS
  • RxBio Inc
  • Soligenix Inc
  • Sunny Pharmtech Inc
  • Synedgen Inc
  • Therapeutic Systems Research Laboratories Inc
  • TheraSource LLC
  • Tonix Pharmaceuticals Holding Corp
  • Valenta Pharm
  • Worphmed Srl

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/k8hss5



Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900